Kazia Therapeutics Ltd expands further in North America with Toronto glioblastoma study

The Sydney-based company’s flagship drug, paxalisib, is a candidate in a multi-drug platform study designed to identify promising new...

Related Keywords

China ,Canada ,Sydney ,New South Wales ,Australia ,Toronto ,Ontario ,Sunnybrook ,Alberta ,Canadians ,Canadian ,James Perry ,University Of Toronto ,Global Coalition For Adaptive Research ,Genentech ,Sunnybrook Health Sciences Centre ,Kazia Therapeutics Ltd ,Nasdaq ,Global Coalition ,Adaptive Research ,Lead Investigator ,Kintara Therapeutics ,Health Sciences Centre ,Orphan Drug Designation ,Fast Track Designation ,Rare Pediatric Disease Designation ,Orphan Designation ,